10 Best Short Squeeze Stocks to Buy According to Analysts

2. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Short % of Float: 16.43%

Number of Hedge Fund Holders: 20

Analysts Upside Potential: 306.98%

Based in Dallas, Texas, a clinical-stage biotechnology company, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) focuses on gene therapies for rare neurological disorders. Unlike most competitors, the company leverages a targeted approach involving AAV-based gene therapy to address central nervous system diseases. Based on its mission statement, the company is developing transformative gene therapies to eradicate monogenic diseases of the central nervous system (CNS).

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has a short interest of 16.43%, positioning it as a candidate for a short squeeze. In the recent quarter, the company has seen increased expenses, including R&D and administrative costs. The expenses are rewarding since the company has announced positive clinical data from its TSHA-102 program. The program showed functional gains in patients with Rett syndrome. Additionally, the company has completed dosing in Part A of its REVEAL trials and is moving toward the pivotal Part B trials. These positive results place the company among the best short-squeeze stocks.

With 20 hedge funds holding stakes in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) from the Insider Monkey database at the end of Q4 2024, the stock has received a Buy rating from analysts, thereby gaining a strong institutional watch. Analysts predict a massive 306.98% upside, setting a price target of $7. At the current price of $1.72, TSHA offers an attractive opportunity for substantial gains driven by short-covering activity.